Navigation Links
Trius Doses First Patient in Antibacterial Phase 2 Trial
Date:9/21/2008

TR-701 Tested for Efficacy in Drug Resistant Skin Infections

SAN DIEGO, Sept. 22 /PRNewswire/ -- Trius Therapeutics, Inc. today announced the initiation of Phase 2 testing of the oral form of its second-generation oxazolidinone antibacterial drug TR-701. The multicenter trial will test the efficacy, safety and tolerability of once-daily doses of 200, 300 and 400 milligrams of TR-701 in complicated skin and skin structure infections (cSSSI) for five to seven days of treatment.

The study follows the recently completed two-part Phase 1 study that tested the safety, tolerability and pharmacokinetics of TR-701 in single and multiple ascending doses for up to 21 days compared with Zyvox(R) (linezolid), the only marketed drug of the oxazolidinone class. In addition, separate food effect and microdialysis studies measuring the absorption of TR-701 in the presence and absence of food and the tissue penetration of the drug, respectively, have also been completed.

Results of the Phase 1 trials will be presented at the joint annual meetings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) in Washington, D.C in October 2008.

"Our Phase 1 study results indicate that TR-701 will be a once-daily drug with the potential to offer patients several important advantages over linezolid as well as other marketed drugs," said Philippe Prokocimer, M.D., Chief Medical Officer of Trius. "The intent of Phase 2 will be to validate these observations in a patient population and to select a therapeutic dosing regimen from the three doses being tested."

"The growing epidemic of MRSA in the hospital and community leaves few viable treatment options for patients requiring an oral drug," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "We believe that the once-daily dosing and short course of TR-701 therapy of five to seven days will offer a clinical advantage fo
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PacificGMP Completes GMP Product Fill for Trius Therapeutics
2. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
5. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
7. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
8. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
9. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
10. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
11. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)...  Teradata (NYSE: TDC ), the ... company, today announced the newest analytic innovation ... Life Sciences helps organizations integrate and analyze data ... (RED), clinical analysis, Real-World Evidence (RWE), and finance. ... can benefit by bringing safer, more effective treatments ...
(Date:4/20/2015)... , April 20, 2015 Pharmaceutical Research and ... $51.2 billion last year in the research and development ... represents the majority of all biopharmaceutical R&D spending – ... United States . The new R&D numbers, the ... are highlighted in the newly released PhRMA ...
(Date:4/20/2015)... Ill. , April 20, 2015  U.S. pharmacy cost ... expected to drift into the low double-digits by 2016, according ... talent, retirement and health solutions business of Aon plc ... design changes are projected to be 9.5 percent in 2015 ... Aon Hewitt predicts a similar rate of increase ...
Breaking Medicine Technology:Teradata Delivers Big Analytics Innovation for Life Sciences 2Teradata Delivers Big Analytics Innovation for Life Sciences 3Teradata Delivers Big Analytics Innovation for Life Sciences 4PhRMA Member Companies Invested $51.2 Billion in R&D in 2014 2PhRMA Member Companies Invested $51.2 Billion in R&D in 2014 3Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 2Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 3Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 4
... Laboratories, Inc. (OTCBB: UGNE), a leader in ... therapeutics, today announced the Company,s Vice President of ... presenting at IBC,s 4th Annual AsiaTIDES Oligonucleotide and ... Hotel in Tokyo, Japan. The TIDES ...
... DIEGO, Feb. 27, 2012 Optimer Pharmaceuticals, Inc. (NASDAQ: ... and fiscal year 2011 financial results and provide a ... the NASDAQ Global Market closes on March 7th.  The ... at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). ...
Cached Medicine Technology:Unigene to Present at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference 2Unigene to Present at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference 3Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and FY 2011 Financial Results 2
(Date:4/20/2015)... 2015 “Consumers deserve to know that their ... children’s hair will not put their health at risk,” said ... National Alliance for Hispanic Health, the nation’s leading Hispanic health ... not had authority to ensure cosmetic and personal care products ... had authority to get products off the shelves if they ...
(Date:4/20/2015)... April 20, 2015 Goodreads is sponsoring ... Insurance: Why It’s Good for You and Your Company ... Zane Pilzer and Rick Lindquist have released a ... Why It’s Good for You and Your Company. The ... health insurance woes - employer-funded individual health insurance. ...
(Date:4/20/2015)... The normal response from the doctor used to be, ... Especially if the patient sought medical care after the six-hour ... different. So it’s critical the patient’s loved ones or caregiver ... , Not every emergency room physician or neurosurgeon has the ... But, according to Ronald P. Benitez , neurosurgeon and ...
(Date:4/20/2015)... Early registration is open for the 2nd ... at the start line. Returning to James Kealoha Beach ... to 500 participants (actually there’s only 499 spots since Big ... Now thru April 30, the entry fee is only $150 ... 1st, the fee goes up to $200 and $100, respectively. ...
(Date:4/20/2015)... Florida Hospital at Connerton Long Term ... from Select Medical, during the annual ceremony hosted at ... Chief Operating Officer, Debi Martoccio, received the Leadership Award ... of six recipients out of 113 hospitals nationwide. The ... for the contributions to the community as well as ...
Breaking Medicine News(10 mins):Health News:Statement of National Alliance for Hispanic Health on Senate Introduction of Personal Care Products Safety Act 2Health News:Zane Benefits Announces Complimentary Book Giveaway On GoodReads: The End of Employer-Provided Health Insurance: Why It's Good for You and Your Company 2Health News:Zane Benefits Announces Complimentary Book Giveaway On GoodReads: The End of Employer-Provided Health Insurance: Why It's Good for You and Your Company 3Health News:"What More Can Be Done?” – The Critical Question That Can Save a Stroke Victim 2Health News:"What More Can Be Done?” – The Critical Question That Can Save a Stroke Victim 3Health News:Hilo Triathlon Kicks Up Its Heels A Second Time; Early Bird Registration Available Online Now. 2Health News:Hilo Triathlon Kicks Up Its Heels A Second Time; Early Bird Registration Available Online Now. 3Health News:Florida Hospital at Connerton Long Term Acute Care Earns Awards from Select Medical including the Stu Dinney Humanitarian Award 2Health News:Florida Hospital at Connerton Long Term Acute Care Earns Awards from Select Medical including the Stu Dinney Humanitarian Award 3
... , , RALEIGH ... SNN ; LSE: SN) Biologics & Spine is proceeding to ... of DUROLANE(R) Single Injection, Stabilized Hyaluronic Acid. , , ... and their global commercial partner, Smith & Nephew met today with ...
... , , , NEW YORK, Aug. ... the beauty industry is the naturals and organic market and HBA Global ... has obtained one of its most well-known innovators and activists to deliver ... the Special Events Hall of the Javits Center in New York. ...
... ... , ... 19, 2009 -- As parents across the country check off school items from their shopping ... season -- foot-friendly shoes. Whether on the school bus, in the classroom or on the ...
... , , , ELM GROVE, Wis., Aug. ... rgency D e partment Core Measures: A ... Comp i rion Healthcare Solutions to aid Hospital Emergency ... for AMI , CHA and CAP patients. Compliance with JCAHO ...
... Alahari, PhD, Associate Professor of Biochemistry and Molecular Biology at ... first time that a tiny piece of RNA appears to ... cancer and identified a gene that appears to inhibit invasive ... 2009 issue of the Journal of Biological Chemistry . ...
... for hand-held technologies , WEDNESDAY, Aug. 19 (HealthDay News) ... to smudge easily, but scientists say they have a ... of protective coatings, a finding that may lead to ... key to anti-smudge coatings is perfluoro alkyl ether, a ...
Cached Medicine News:Health News:Smith & Nephew Takes Single Injection PMA to Next Stage 2Health News:Smith & Nephew Takes Single Injection PMA to Next Stage 3Health News:Smith & Nephew Takes Single Injection PMA to Next Stage 4Health News:Horst M. Rechelbacher To Deliver HBA Global Expo Keynote Address 2Health News:Horst M. Rechelbacher To Deliver HBA Global Expo Keynote Address 3Health News:Give Shoes the '1,2,3 Test' During Back-To-School Shopping 2Health News:Give Shoes the '1,2,3 Test' During Back-To-School Shopping 3Health News:Compirion Hosts Free Webinar on Achieving JCAHO-Compliant Quality Outcomes 2Health News:Compirion Hosts Free Webinar on Achieving JCAHO-Compliant Quality Outcomes 3Health News:LSUHSC research discovers new targets for treatment of invasive breast cancer 2Health News:A Smudge-Free Smart Phone Screen? 2
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Medicine Products: